Research analysts at StockNews.com started coverage on shares of ADMA Biologics (NASDAQ:ADMA – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Several other equities analysts also recently weighed in on ADMA. Mizuho lifted their target price on ADMA Biologics from $6.00 to $7.00 in a research report on Thursday, August 10th. Cantor Fitzgerald upped their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. HC Wainwright boosted their price target on shares of ADMA Biologics from $4.50 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Finally, Raymond James increased their price objective on ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.00.
View Our Latest Analysis on ADMA
ADMA Biologics Trading Up 2.1 %
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). ADMA Biologics had a negative net margin of 19.36% and a negative return on equity of 27.55%. The firm had revenue of $60.12 million during the quarter, compared to the consensus estimate of $55.45 million. During the same quarter last year, the firm earned ($0.07) EPS. On average, analysts predict that ADMA Biologics will post -0.06 EPS for the current year.
Insider Activity
In other ADMA Biologics news, Director Young Kwon bought 25,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were purchased at an average price of $3.90 per share, with a total value of $97,500.00. Following the completion of the acquisition, the director now directly owns 277,401 shares of the company’s stock, valued at approximately $1,081,863.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Young Kwon purchased 25,000 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were bought at an average cost of $3.90 per share, for a total transaction of $97,500.00. Following the completion of the purchase, the director now directly owns 277,401 shares of the company’s stock, valued at approximately $1,081,863.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bryant Fong sold 1,433,304 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $3.87, for a total transaction of $5,546,886.48. Following the sale, the director now owns 59,901 shares of the company’s stock, valued at approximately $231,816.87. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,405,351 shares of company stock worth $9,875,175. 6.00% of the stock is currently owned by corporate insiders.
Institutional Trading of ADMA Biologics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Pictet Asset Management SA lifted its stake in ADMA Biologics by 46.4% in the first quarter. Pictet Asset Management SA now owns 32,474 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 10,295 shares during the last quarter. Inspire Investing LLC purchased a new position in ADMA Biologics during the 1st quarter worth $540,000. Globeflex Capital L P acquired a new position in ADMA Biologics in the first quarter valued at $782,000. EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics in the first quarter valued at about $331,000. Finally, Profund Advisors LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $604,000. Institutional investors and hedge funds own 73.58% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
- Five stocks we like better than ADMA Biologics
- How to Capture the Benefits of Dividend Increases
- Huawei Has Entered The Chips Race, Markets Still Prefer These
- 3 Small Caps With Big Return Potential
- Restaurant Stocks Go on Sale…Which Are Really on the Value Menu?
- Dividend Tax Calculator
- 5 Reasons to Buy and Hold Exxon Mobil For 2024
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
